Furthermore, PTEN loss in NSCLC tumors could lead to the development of an immunosuppressive microenvironment resulting in resistance to anti-PD-1 therapy, which can be overcome by targeting the immunosuppression mediated by PTEN loss [121]. Here, PDCD1 is linked to non-small cell lung carcinoma.